BUZZ-Xenon 股价因计划增资而下挫,此前癫痫药物数据强劲

路透中文
Yesterday
BUZZ-Xenon 股价因计划增资而下挫,此前癫痫药物数据强劲

3月9日 - ** Xenon Pharmaceuticals XENE.O股价在延时交易中下跌约1%,该公司在癫痫药物晚期试验达到主要目标后寻求股票融资

** XENE股价飙升49.6%,收盘价达到62.76美元,创下历史新高,原因是该公司的药物azetukalner显示 (link),在12周内,25毫克剂量下每月癫痫发作频率中位数减少53.2%,15毫克剂量下减少34.5%,而安慰剂减少10.4%。

** 公司在收盘后开始 (link) 5 亿美元的股票发行

** JP Morgan、Jefferies、TD Cowen、Stifel、RBC 和 William Blair 为联合账簿管理人

** 总部位于加拿大的 XENE 拥有约 8,320 万股已发行股票,市值约 52 亿美元。

** 截至收盘,股价在过去 12 个月中上涨了约 72%

** 根据 LSEG 的数据,在 21 位覆盖该股的分析师中,9 位 "强烈买入",12 位 "买入";PT 中值为 74.50 美元,高于一个月前的 55 美元。

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10